NCT03507738View on ClinicalTrials.gov

Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions
Healthy
Interventions
BIOLOGICAL

MT-5625 low dose

Intramuscular injection

BIOLOGICAL

MT-5625 middle dose

Intramuscular injection

BIOLOGICAL

MT-5625 high dose

Intramuscular injection

BIOLOGICAL

Rotarix

Oral administration

BIOLOGICAL

Placebo

Intramuscular injection

Trial Locations (2)

Unknown

Investigational center, Adelaide

Investigational center, Johannesburg

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY